Performance of plasminogen activator inhibitor-1 as a biomarker in patients undergoing coronary angiography: Analytical and biological considerations
Autor: | Rebecca Rochman, Kamran Majeed, Richard G. Jung, Young Jung, Robert Moreland, Benjamin Hibbert, Anne Claire Duchez, Trevor Simard, Pietro Di Santo, Pouya Motazedian, Alisha Labinaz |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
Target lesion Coronary angiography medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Clinical Decision-Making Coronary Artery Disease 030204 cardiovascular system & hematology Coronary Angiography Risk Assessment Coronary artery disease 03 medical and health sciences chemistry.chemical_compound Percutaneous Coronary Intervention 0302 clinical medicine Predictive Value of Tests Risk Factors Internal medicine Plasminogen Activator Inhibitor 1 Internal Medicine medicine Humans In patient Prospective Studies Registries Aged 030304 developmental biology 0303 health sciences business.industry Percutaneous coronary intervention Middle Aged Prognosis medicine.disease chemistry Plasminogen activator inhibitor-1 Cardiology Biomarker (medicine) Female Cardiology and Cardiovascular Medicine business Medical therapy Biomarkers |
Zdroj: | Diabetes and Vascular Disease Research. 16:478-482 |
ISSN: | 1752-8984 1479-1641 |
DOI: | 10.1177/1479164119845123 |
Popis: | Introduction and objective:Target lesion failure continues to limit the efficacy of percutaneous coronary intervention despite advancements in stent design and medical therapy. Identification of biomarkers to risk stratify patients after percutaneous coronary intervention has the potential to focus therapies on cohorts with increased benefits. Plasminogen activator inhibitor-1 has been identified as a candidate biomarker. Herein, we evaluate biological variables which impact plasminogen activator inhibitor-1 levels and analytical characteristics which impact its utility as a biomarker in humans.Methods:Plasma plasminogen activator inhibitor-1 was measured in 689 patients undergoing coronary angiography. Plasminogen activator inhibitor-1 levels were measured. Clinical and procedural characteristics were collected in a prospective registry.Results:Plasma plasminogen activator inhibitor-1 analytical ( CVa= 4.1%), intra-individual ( CVi= 44.0%) and inter-individual ( CVg= 118.6%) variations with reference change value of 122.3% were calculated. Plasminogen activator inhibitor-1 levels were elevated in patients with cardiovascular risk factors, including type 2 diabetes, pre-diabetes, smokers, obesity, hypertension, and daytime variation in procedure and blood draw.Conclusion:Variation in plasma plasminogen activator inhibitor-1 levels is influenced by multiple biological and procedural characteristics. The performance of plasma plasminogen activator inhibitor-1 is consistent with biomarkers in clinical use (N-terminal pro-B-type natriuretic peptide and C-reactive protein) and its applicability is promising. |
Databáze: | OpenAIRE |
Externí odkaz: |